HIV-1 envelope gp41 broadly neutralizing antibodies: hurdles for vaccine development.
Publication
, Journal Article
Verkoczy, L; Kelsoe, G; Haynes, BF
Published in: PLoS Pathog
May 2014
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
PLoS Pathog
DOI
EISSN
1553-7374
Publication Date
May 2014
Volume
10
Issue
5
Start / End Page
e1004073
Location
United States
Related Subject Headings
- Virology
- Mutation
- Immune Tolerance
- Humans
- HIV-1
- HIV Infections
- HIV Envelope Protein gp41
- HIV Antibodies
- Drug Discovery
- Autoantibodies
Citation
APA
Chicago
ICMJE
MLA
NLM
Verkoczy, L., Kelsoe, G., & Haynes, B. F. (2014). HIV-1 envelope gp41 broadly neutralizing antibodies: hurdles for vaccine development. PLoS Pathog, 10(5), e1004073. https://doi.org/10.1371/journal.ppat.1004073
Verkoczy, Laurent, Garnett Kelsoe, and Barton F. Haynes. “HIV-1 envelope gp41 broadly neutralizing antibodies: hurdles for vaccine development.” PLoS Pathog 10, no. 5 (May 2014): e1004073. https://doi.org/10.1371/journal.ppat.1004073.
Verkoczy L, Kelsoe G, Haynes BF. HIV-1 envelope gp41 broadly neutralizing antibodies: hurdles for vaccine development. PLoS Pathog. 2014 May;10(5):e1004073.
Verkoczy, Laurent, et al. “HIV-1 envelope gp41 broadly neutralizing antibodies: hurdles for vaccine development.” PLoS Pathog, vol. 10, no. 5, May 2014, p. e1004073. Pubmed, doi:10.1371/journal.ppat.1004073.
Verkoczy L, Kelsoe G, Haynes BF. HIV-1 envelope gp41 broadly neutralizing antibodies: hurdles for vaccine development. PLoS Pathog. 2014 May;10(5):e1004073.
Published In
PLoS Pathog
DOI
EISSN
1553-7374
Publication Date
May 2014
Volume
10
Issue
5
Start / End Page
e1004073
Location
United States
Related Subject Headings
- Virology
- Mutation
- Immune Tolerance
- Humans
- HIV-1
- HIV Infections
- HIV Envelope Protein gp41
- HIV Antibodies
- Drug Discovery
- Autoantibodies